Subsidiary – Reponex Pharmaceuticals (new)
Pharma Equity Group operates through its subsidiary, Reponex Pharmaceuticals A/S, which repurposes existing active substances for new therapeutic uses.
Pharma Equity Group is a publicly listed life science investment company licensing drug candidates to pharmaceutical companies.
pharmaequitygroup.comCrawled Nov 13, 2026
Pharma Equity Group operates through its subsidiary, Reponex Pharmaceuticals A/S, which repurposes existing active substances for new therapeutic uses.
Chronic skin ulcers, such as venous leg ulcers and diabetic ulcers, require specialized treatments, including debridement of necrotic tissue.
Colorectal Cancer & Colon Adenomas Recent findings reveal that the development, growth, and spread of colorectal cancer tumors are influenced by specific bacteria in the large bowel. Among these bacteria are toxin-producing fusobacteria that form biofilms and penetrate the bowel's surface mucous layer. Some of these bacteria even infect bowel cancers, promoting tumor growth and
Denmark has seen a rise in Inflammatory Bowel Disease (IBD) cases, including Crohn’s disease, which tripled from 1995 to 2016.
Repositioning known drugs into new intervention is the heart of what we do. Reponex drug candidate overview By repositioning our subsidiary Reponex finds new uses for active substances that are being used in other treatments. This means that the substances are used for other treatments than it was originally designated and registered for. The advantage
Reponex Pharmaceuticals focuses its peritonitis program on treating bacterial peritonitis and preventing its recurrence in complex abdominal infections.
The company provides a media resource library with brand assets, including logos and executive headshots, alongside video resources.
The company prioritizes transparency with stakeholders by ensuring all published materials are accessible.
The company shares press releases and announcements, including Reponex Pharmaceuticals’ listing on the Copenhagen Stock Exchange.
The page lists upcoming and past events, presentations, and slide decks related to Pharma Equity Group.
The company communicates about its drug candidates and the biopharmaceutical industry’s role in patient and societal benefit.
Pharma Equity Group provides prospectus and documentation for Reponex and capital increase activities, restricted to eligible recipients.
The company offers video presentations and multimedia content explaining its work and drug development process.
Pharma Equity Group supports Reponex Pharmaceuticals in achieving clinical and financial objectives.
Christian Vinding Thomsen, Chairman of the Board, has over 20 years of experience in regulatory life science, healthcare, and corporate law.
The board has established committees—Audit, Remuneration, Nomination, and Business, Research and Development—to advise on specific operational areas.
The board committees advise on specific areas of operations.
Key Figures Last Updated February 2023 Share Capital 1.022.963.883 DKK Share Size 1.00 DKK Noted Capital/Number of shares 1.022.963.883 Stock Exchange code/ISIN DK0061155009 Short Name PEG A
Pharma Equity Group and Reponex are led by a team of experts focused on long-term success.
Pharma Equity Group promotes equal opportunities for employees based on gender, age, religion, sexual orientation, and ethnicity.
Pharma Equity Group aims to develop effective local treatments for inflammatory diseases and reposition existing drugs.
The company’s corporate governance statements comply with the Danish Financial Statement Act and appear in the annual report for 2025.
The company follows corporate governance recommendations from the Committee on Corporate Governance to maximize shareholder value.
Pharma Equity Group invests in and develops biopharmaceutical companies to address unmet medical needs.
The company describes its internal control and risk management systems in its 2025 annual report under section 107b of the Danish Financial Statements Act.
Pharma Equity Group is a clinical phase two company listed on the Nasdaq Copenhagen stock exchange.
Interpatium filed a lawsuit in Helsingør District Court to overturn a EUR 10.5 million arbitral award—plus interest and costs—granted to Pharma Equity Group A/S (PEG). The case challenges the validity of the June 12, 2026 ruling, which favored PEG in the dispute. The court proceedings now aim to annul the arbitral decision.
Pharma Equity Group reports a **DKK 2.7 million loss** for the first half of 2026. The company strengthens its **inflammatory bowel disease (IBD) patent portfolio**, advances **RNX-051** with national-phase filings, and secures a **Portinho receivable arbitral award**. These developments reflect ongoing efforts to bolster its pipeline and financial position amid operational challenges.
Reponex, a subsidiary of Pharma Equity Group, receives a European patent grant notification for compositions and methods targeting inflammatory bowel disease. The patent covers novel approaches to treating the condition, marking a significant advancement in Reponex’s pipeline. This development follows the company’s focus on gastrointestinal therapies.
Pharma Equity Group A/S reports a **DKK -25.4 million loss** for 2025 while securing **pivotal Phase 2 approval for RNX-011**. The company also advances partnering discussions for its asset **RNX-051**, though no formal agreements are announced. The report highlights progress in its clinical pipeline amid financial challenges.
Reponex Pharmaceuticals A/S demonstrates a **30-fold reduction in bowel-lining biofilm** in the adenoma arm of its Phase 2 MEFO trial for the patented drug candidate **RNX-051**. The final results confirm significant efficacy in addressing biofilm-related conditions. The trial marks a key milestone for the company’s pipeline under Pharma Equity Group’s subsidiary structure.